

# Anti-MSLN (Anetumab), Human IgG1 Antibody

12/20

---

**CATALOG NO.:** A2272-100 (100 µg)

---

**BACKGROUND DESCRIPTION:** The research-grade biosimilar is a recombinant antibody to Anetumab without the drug conjugation. The original antibody-drug conjugate (Anetumab Ravtansine) consists of an anti-mesothelin (MSLN) human IgG1 antibody conjugated to DM4, an anti-tumor chemical derivative of maytansine via a disulfide-containing cleavable sulfo-SPDB linker. Upon interaction and internalization by MSLN expressing tumor cells, the DM4 is detached from the antibody due to proteolytic cleavage. The DM4 then inhibits polymerization of the tubulin and disrupts the microtubule assembly, thereby leading to cell cycle arrest and apoptosis. The original antibody-drug conjugate is used as an investigational agent to treat pancreatic, ovarian cancer, and advanced or recurrent mesothelioma.

**ALTERNATE NAMES:** MPF, SMRP, MSLN, Mesothelin, CAK1, CAK1 Antigen

**ANTIBODY TYPE:** Monoclonal

**HOST/ISOTYPE:** Recombinant / IgG1, lambda

**SOURCE:** CHO cells

**IMMUNOGEN:** Human MSLN

**CAS NUMBER:** 1375258-01-7

**PURIFICATION:** Protein A purified

**FORM:** Liquid

**FORMULATION:** In PBS, pH 7.5

**SPECIES REACTIVITY:** Human

**STORAGE CONDITIONS:** Store at -80°C. Avoid freeze/thaw cycles

**This information is only intended as a guide. The optimal dilutions must be determined by the user**

**RELATED PRODUCTS:**

Anti-PCSK9 (Alirocumab), Human IgG1 Antibody (A2153)

Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)

Anti-CTLA-4 (Ipilimumab), Humanized Antibody (A2110)

Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)

Anti-IL-6 (Siltuximab), Chimeric Antibody (A2143)

**FOR RESEARCH USE ONLY! Not to be used on humans.**